Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE: 300573)
Health Care · Pharmaceuticals · CN
CN¥39.75
-2.76% today · -14.6% 1Y
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE: 300573) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.11B and employs 2,396 people.
Over the last twelve months the share price has lost 14.6%, trading between 35.10 and 59.07.
Tweenvest scores Shenyang Xingqi Pharmaceutical Co.,Ltd. across four factors: quality 84/100, value 76/100, growth 100/100, dividend 71/100. Its strongest factor is growth.
300573 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.11B
- Revenue (TTM)
- $379.86M
- P/E
- 18.71
- EPS
- 2.12
- Dividend yield
- 2.87%
- Beta (5Y)
- 0.10
- 52-week high
- CN¥59.07
- 52-week low
- CN¥35.10
- Avg volume (3M)
- —
- Shares outstanding
- 357.32M
- Employees
- 2,396
- Next earnings
- —
About Shenyang Xingqi Pharmaceutical Co.,Ltd.
Shenyang Xingqi Pharmaceutical Co., Ltd, based in Shenyang, China, specializes in the comprehensive process of creating, producing, and distributing ophthalmological products throughout the Chinese market. The company offers a diverse portfolio of eye care solutions, which includes items for corneal health, anti-bacterial applications, artificial tear substitutes, anti-inflammatory medications, surgical perfusion liquids, mydriatic agents, anti-fatigue treatments, and specific therapies for both incipient and severe dry eye conditions.
- ISIN
- CNE100002DV1
- Founded
- 1977
- Listed since
- Dec 9, 2016
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.38 | +0.54% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.